184 related articles for article (PubMed ID: 12412820)
1. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.
Belle DJ; Ernest CS; Sauer JM; Smith BP; Thomasson HR; Witcher JW
J Clin Pharmacol; 2002 Nov; 42(11):1219-27. PubMed ID: 12412820
[TBL] [Abstract][Full Text] [Related]
2. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
3. Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.
Byeon JY; Kim YH; Na HS; Jang JH; Kim SH; Lee YJ; Bae JW; Kim IS; Jang CG; Chung MW; Lee SY
Arch Pharm Res; 2015 Nov; 38(11):2083-91. PubMed ID: 26254792
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.
Choi CI; Bae JW; Lee YJ; Lee HI; Jang CG; Lee SY
J Clin Psychopharmacol; 2014 Feb; 34(1):139-42. PubMed ID: 24346747
[TBL] [Abstract][Full Text] [Related]
5. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
7. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
[TBL] [Abstract][Full Text] [Related]
9. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Paulzen M; Clement HW; Gründer G
Int J Neuropsychopharmacol; 2008 Mar; 11(2):289-91. PubMed ID: 18215333
[No Abstract] [Full Text] [Related]
12. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
13. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
[TBL] [Abstract][Full Text] [Related]
14. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.
Witcher JW; Long A; Smith B; Sauer JM; Heilgenstein J; Wilens T; Spencer T; Biederman J
J Child Adolesc Psychopharmacol; 2003; 13(1):53-63. PubMed ID: 12804126
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.
Cui YM; Teng CH; Pan AX; Yuen E; Yeo KP; Zhou Y; Zhao X; Long AJ; Bangs ME; Wise SD
Br J Clin Pharmacol; 2007 Oct; 64(4):445-9. PubMed ID: 17610534
[TBL] [Abstract][Full Text] [Related]
17. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
18. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
Ozdemir V; Naranjo CA; Herrmann N; Reed K; Sellers EM; Kalow W
Clin Pharmacol Ther; 1997 Sep; 62(3):334-47. PubMed ID: 9333110
[TBL] [Abstract][Full Text] [Related]
20. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite.
Todor I; Popa A; Neag M; Muntean D; Bocsan C; Buzoianu A; Vlase L; Gheldiu AM; Chira R; Briciu C
Clujul Med; 2015; 88(4):513-20. PubMed ID: 26733750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
